Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Block-randomized, Double-blinded, Placebo-controlled, Single-dose, Dose-escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of HL-032 in Healthy Male Volunteers

NCT01440686 is registered in ClinicalTrials.gov with HanAll BioPharma Co., Ltd. as lead sponsor.

NCT NCT01440686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01440686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Block-randomized, Double-blinded, Placebo-controlled, Single-dose, Dose-escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of HL-032 in Healthy Male Volunteers
Lead sponsor
HanAll BioPharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
January 31, 2012
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency